Disruptive But Profitable: PricewaterhouseCoopers Projects 11 Percent Annual Growth for Personalized Rx | GenomeWeb

By Turna Ray

In the effort to align personalized medicine and comparative effectiveness research, the Agency for Healthcare Quality & Research will continue to gather evidence on the clinical utility and validity of genetic tests that guide informed healthcare decision making, director Carolyn Clancy said at a recent meeting in Washington, DC.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.